A Partnership That’s Changing the Way India Prescribes In a landmark move, AIG Hospitals has partnered with GenePoweRx to introduce Pharmacogenomics (PGx) testing, bringing the future of precision medicine to India.
Glimpse:
This collaboration integrates genetic intelligence into clinical care, allowing doctors to prescribe drugs based on an individual’s DNA rather than one-size-fits-all guidelines. With GenePoweRx’s AI-powered genomic interpretation engine, doctors can now predict how patients will respond to medications reducing adverse drug reactions, improving treatment outcomes, and enhancing safety.
Why It Matters
When AIG Hospitals tested over 2,000 patients on medications for diabetes, hypertension, and ulcers, the results were striking nearly 30 percent were taking drugs unsuitable for their genetic makeup.
This revelation underscored a critical gap: textbook prescriptions often fail to consider India’s unique genetic diversity.
Through pharmacogenomic testing, AIG aims to bridge the gap between Western data and Indian genetics, ensuring that every prescription is backed by science that fits the patient not just the textbook.
How It Works
Seamless integration within AIG’s clinical workflow from prescription to post-test guidance.
AI-driven genomic engine aligns genetic data with global standards like CPIC, PharmGKB, and FDA guidelines.
Actionable insights for doctors helping determine the right drug, right dose, and right duration for each patient.
For just ₹5,000, a small blood sample analyses 120 genes, producing a lifelong personalised medication report a roadmap for safe, effective treatment.
From Harvard to Hyderabad: The Science Behind It
Two physician-scientists, Dr. Hima Challa (Harvard-trained in genomics) and Dr. Kalyan Uppaluri (Stanford-trained internist), brought cutting-edge pharmacogenomic expertise to India.
“The FDA now recommends genetic biomarkers for many drugs because the same dose doesn’t work uniformly across individuals,” says Dr. Challa.
Under Dr. Reddy’s mentorship, AIG’s research followed global scientific standards and the findings were “eye-opening.”
A Future of Precision Care
In about 30 percent of patients, dosages had to be adjusted some needed higher doses, others lower.
“This clearly shows that without genetic insights, we risk prescribing the wrong medicines,” says Dr. Reddy.
With pharmacogenomic testing now part of AIG’s care ecosystem, the hospital is leading India toward a new era of precision medicine
where treatment is no longer by the book, but by your DNA.
“Personalized medicine, driven by genomics, is the future,” Dr. D. Nageshwar Reddy, Chairman, AIG Hospitals
By
HB Team
